FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379197694> ?p ?o ?g. }

• W4379197694 abstract "Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections play a key role in treating a range of macular diseases. The effectiveness of these therapies is dependent on patients' adherence (the extent to which a patient takes their medicines as per agreed recommendations from the healthcare provider) and persistence (continuation of the treatment for the prescribed duration) to their prescribed treatment regimens. The aim of this systematic review was to demonstrate the need for further investigation into the prevalence of, and factors contributing to, patient-led non-adherence and non-persistence, thus facilitating improved clinical outcomes.Systematic searches were conducted in Google Scholar, Web of Science, PubMed, MEDLINE, and the Cochrane Library. Studies in English conducted before February 2023 that reported the level of, and/or barriers to, non-adherence or non-persistence to intravitreal anti-VEGF ocular disease therapy were included. Duplicate papers, literature reviews, expert opinion articles, case studies, and case series were excluded following screening by two independent authors.Data from a total of 409,215 patients across 52 studies were analysed. Treatment regimens included pro re nata, monthly and treat-and-extend protocols; study durations ranged from 4 months to 8 years. Of the 52 studies, 22 included a breakdown of reasons for patient non-adherence/non-persistence. Patient-led non-adherence varied between 17.5 and 35.0% depending on the definition used. Overall pooled prevalence of patient-led treatment non-persistence was 30.0% (P = 0.000). Reasons for non-adherence/non-persistence included dissatisfaction with treatment results (29.9%), financial burden (19%), older age/comorbidities (15.5%), difficulty booking appointments (8.5%), travel distance/social isolation (7.9%), lack of time (5.8%), satisfaction with the perceived improvement in their condition (4.4%), fear of injection (4.0%), loss of motivation (4.0%), apathy towards eyesight (2.5%), dissatisfaction with facilities 2.3%, and discomfort/pain (0.3%). Three studies found non-adherence rates between 51.6 and 68.8% during the COVID-19 pandemic, in part due to fear of exposure to COVID-19 and difficulties travelling during lockdown.Results suggest high levels of patient-led non-adherence/non-persistence to anti-VEGF therapy, mostly due to dissatisfaction with treatment results, a combination of comorbidities, loss of motivation and the burden of travel. This study provides key information on prevalence and factors contributing to non-adherence/non-persistence in anti-VEGF treatment for macular diseases, aiding identification of at-risk individuals to improve real-world visual outcomes. Improvements in the literature can be achieved by establishing uniform definitions and standard timescales for what constitutes non-adherence/non-persistence.PROSPERO CRD42020216205." @default.
• W4379197694 created "2023-06-04" @default.
• W4379197694 creator A5006046298 @default.
• W4379197694 creator A5012793038 @default.
• W4379197694 creator A5019257779 @default.
• W4379197694 creator A5023331080 @default.
• W4379197694 creator A5042407608 @default.
• W4379197694 creator A5044194965 @default.
• W4379197694 creator A5074056939 @default.
• W4379197694 creator A5082005077 @default.
• W4379197694 creator A5090528267 @default.
• W4379197694 date "2023-06-02" @default.
• W4379197694 modified "2023-09-30" @default.
• W4379197694 title "Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis" @default.
• W4379197694 cites W1044276697 @default.
• W4379197694 cites W1481978003 @default.
• W4379197694 cites W1845225129 @default.
• W4379197694 cites W1992612246 @default.
• W4379197694 cites W2003324689 @default.
• W4379197694 cites W2007177737 @default.
• W4379197694 cites W2015457963 @default.
• W4379197694 cites W2017194458 @default.
• W4379197694 cites W2029718336 @default.
• W4379197694 cites W2054061193 @default.
• W4379197694 cites W2063420400 @default.
• W4379197694 cites W2071317073 @default.
• W4379197694 cites W2078326688 @default.
• W4379197694 cites W2089092235 @default.
• W4379197694 cites W2113033841 @default.
• W4379197694 cites W2138802622 @default.
• W4379197694 cites W2146673937 @default.
• W4379197694 cites W2161606648 @default.
• W4379197694 cites W2263495255 @default.
• W4379197694 cites W2322467860 @default.
• W4379197694 cites W2504883101 @default.
• W4379197694 cites W2529823218 @default.
• W4379197694 cites W2620988129 @default.
• W4379197694 cites W2742297576 @default.
• W4379197694 cites W2746562707 @default.
• W4379197694 cites W2766315223 @default.
• W4379197694 cites W2770668652 @default.
• W4379197694 cites W2777721386 @default.
• W4379197694 cites W2799551240 @default.
• W4379197694 cites W2888464051 @default.
• W4379197694 cites W2899990204 @default.
• W4379197694 cites W2962378670 @default.
• W4379197694 cites W2991774595 @default.
• W4379197694 cites W2994865070 @default.
• W4379197694 cites W2997714006 @default.
• W4379197694 cites W2998338608 @default.
• W4379197694 cites W3005006385 @default.
• W4379197694 cites W3005239446 @default.
• W4379197694 cites W3012913714 @default.
• W4379197694 cites W3022911069 @default.
• W4379197694 cites W3035825207 @default.
• W4379197694 cites W3041333867 @default.
• W4379197694 cites W3047590017 @default.
• W4379197694 cites W3048627786 @default.
• W4379197694 cites W3049752044 @default.
• W4379197694 cites W3081452574 @default.
• W4379197694 cites W3089306714 @default.
• W4379197694 cites W3090495755 @default.
• W4379197694 cites W3093144182 @default.
• W4379197694 cites W3107445121 @default.
• W4379197694 cites W3153833523 @default.
• W4379197694 cites W3164934199 @default.
• W4379197694 cites W3169312712 @default.
• W4379197694 cites W3183125882 @default.
• W4379197694 cites W3200501633 @default.
• W4379197694 cites W3210338505 @default.
• W4379197694 cites W3212594963 @default.
• W4379197694 cites W4205593141 @default.
• W4379197694 cites W4206628584 @default.
• W4379197694 cites W4210909781 @default.
• W4379197694 cites W4224277431 @default.
• W4379197694 cites W4225412252 @default.
• W4379197694 cites W4226146842 @default.
• W4379197694 cites W4281298455 @default.
• W4379197694 cites W4281571934 @default.
• W4379197694 cites W4281902324 @default.
• W4379197694 cites W4282945787 @default.
• W4379197694 cites W4283216963 @default.
• W4379197694 cites W4296350550 @default.
• W4379197694 cites W4322487813 @default.
• W4379197694 cites W981032783 @default.
• W4379197694 cites W2898637562 @default.
• W4379197694 doi "https://doi.org/10.1186/s13643-023-02261-x" @default.
• W4379197694 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37269003" @default.
• W4379197694 hasPublicationYear "2023" @default.
• W4379197694 type Work @default.
• W4379197694 citedByCount "1" @default.
• W4379197694 countsByYear W43791976942023 @default.
• W4379197694 crossrefType "journal-article" @default.
• W4379197694 hasAuthorship W4379197694A5006046298 @default.
• W4379197694 hasAuthorship W4379197694A5012793038 @default.
• W4379197694 hasAuthorship W4379197694A5019257779 @default.
• W4379197694 hasAuthorship W4379197694A5023331080 @default.
• W4379197694 hasAuthorship W4379197694A5042407608 @default.
• W4379197694 hasAuthorship W4379197694A5044194965 @default.
• W4379197694 hasAuthorship W4379197694A5074056939 @default.

• next